Université de Franche-Comté, Besançon, France. ⁵Dept of Physiology and EA 3920, University Hospital, Besançon, France.

Correspondence: Bruno Degano, Explorations Fonctionnelles – Physiologie, CHU de Besançon, Boulevard Fleming, 25000 Besançon, France. E-mail: bruno.degano@univ-fcomte.fr

Received: May 13 2014 | Accepted after revision: June 15 2014

Conflict of interest: None declared.

Provenance: Submitted article, peer reviewed.

References

- Hegewald MJ, Crapo RO. Respiratory physiology in pregnancy. Clin Chest Med 2011; 32: 1–13.
- 2 Melot C, Naeije R. Pulmonary vascular diseases. Compr Physiol 2011; 1: 593-619.
- 3 Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. *Am J Obstet Gynecol* 2013; 208: 102–108.
- 4 Pernot J, Puzenat E, Magy-Bertrand N, *et al.* Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide. *Respiration* 2012; 84: 461–468.
- 5 Degano B, Mittaine M, Guenard H, et al. Nitric oxide and carbon monoxide lung transfer in patients with advanced liver cirrhosis. J Appl Physiol 2009; 107: 139–143.
- 6 Swinburne AJ, Fedullo AJ, Gangemi R, et al. Hereditary telangiectasia and multiple pulmonary arteriovenous fistulas. Clinical deterioration during pregnancy. Chest 1986; 89: 459–460.
- 7 Degano B, Mittaine M, Herve P, *et al*. Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients. *Eur Respir J* 2009; 34: 138–144.
- Wagner PD, Rodriguez-Roisin R. Clinical advances in pulmonary gas exchange. Am Rev Respir Dis 1991; 143: 883–888.
 Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome a liver-induced lung vascular disorder. N Engl J
- Med 2008; 358: 2378–2387.
- 10 Degano B, Mourlanette P, Valmary S, *et al.* Differential effects of low and high-dose estradiol on airway reactivity in ovariectomized rats. *Respir Physiol Neurobiol* 2003; 138: 265–274.
- 11 Tunzi M, Gray GR. Common skin conditions during pregnancy. Am Fam Physician 2007; 75: 211–218.
- 12 Wilmshurst P, Jackson P. Arterial hypoxemia during pregnancy caused by pulmonary arteriovenous microfistulas. *Chest* 1996; 110: 1368–1369.

Eur Respir Rev 2014; 23: 531–533 | DOI: 10.1183/09059180.00003514 | Copyright ©ERS 2014 ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Pulmonary hypertension associated with Whipple disease

To the Editor:

Whipple disease is a rare multi-systemic disorder caused by *Thropheryma whipplei*, a Gram-positive bacillus. Gastrointestinal manifestations are the most frequent, but many other organs may be involved [1, 2]. Pulmonary hypertension (PH) associated with Whipple disease is extremely rare, and only a few isolated cases have been reported. We present two patients with PH-Whipple disease with a positive vasodilator test and excellent response to antibiotic therapy.

Patient 1

A 72-year-old Caucasian male with an 8-month history of intermittent abdominal pain and diarrhoea presented with dyspnoea on exertion that had progressed in the last 4 months (functional class III) and two-pillow orthopnoea to keep his head at 30° . He reported weight loss of 6 kg during the preceding 8 months. A colonoscopy performed 15 days before showed only nonspecific inflammation. Past medical history included mild chronic obstructive pulmonary disease treated with ipratropium. Physical examination revealed hypotension (systolic arterial pressure 90 mmHg) and bibasilar rales but not lower leg oedema. Laboratory data showed haemoglobin of 94 g·L⁻¹ and albumin of 19 g·L⁻¹. Antinuclear antibodies, rheumatoid factor and a HIV test were negative. A chest computed tomography (CT) with embolism protocol demonstrated bilateral pleural and pericardial effusions and mediastinal adenopathy. No emboli were found in the pulmonary arteries. Abdominal CT showed mild ascites and multiple small lymph nodes. Gastroduodenoscopy demonstrated diffuse inflammation in the duodenum. Small bowel biopsies showed typical periodic acid–Schiff (PAS)-positive diastase-resistant histiocytes. Several days later PCR confirmed the presence of *T. whipplei*. Transthoracic echocardiography showed normal left cavities with a

ABLE I Haemodynamic studies of the two patients pre- and post-vasodi	dilator tes	stina
--	-------------	-------

	dPAP mmHg	mPAP mmHg	sPAP mmHg	PCWP [#] mmHg	CI L·m ⁻¹ ·m ⁻²	PVR Wood unit
Pre-vasodilator test						
Case 1	29	34	47	10	2.05	6.7
Case 2	33	52	87	14	2.3	7.91
Post-vasodilator test						
Case 1	20	25	34	9	3.1	3.9
Case 2	23	39	65	12	3.8	3.1

dPAP: diastolic pulmonary arterial pressure; mPAP: mean pulmonary artery pressure; sPAP systolic pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; CI: cardiac index; PVR pulmonary vascular resistance. [#]: both patients showed PCWP within normal limits.

dilated right ventricle (55 mm). The velocity of the tricuspid jet was 3.68 m·s⁻¹ with an estimated systolic pulmonary artery pressure (sPAP) of 64 mmHg. A ventilation/perfusion scan excluded thromboembolic disease. Right heart catheterisation confirmed the diagnosis of PH (table 1). A vasodilator test with epoprostenol revealed a positive response with a 12 mmHg decrease of mean pulmonary artery pressure (mPAP) and ~1 L·m⁻¹·m⁻² increase of cardiac index. A 4-week course of 2 g ceftriaxone per 24 h was started followed by trimethoprim/sulfamethoxazole 160/800 µg. 2 months later the patient was much better (functional class I) with N-terminal pro-brain natriuretic peptide (NT-proBNP) 288 pg·mL⁻¹. An echocardiogram was performed with near normal values (right ventricle 36 mm) and minimal tricuspid insufficiency. After 10 months of treatment all symptoms resolved and a new echocardiogram was normal.

Patient 2

A 66-year-old Caucasian male doctor was admitted with worsening dyspnoea and near-syncope. He had been a mild smoker 20 years previously and showed moderate airflow obstruction (forced expiratory volume in 1 s 52%), which was treated with tiotropium. In the previous year he had received several courses of non-steroidal anti-inflammatory drugs and prednisone because of spinal and polyarticular pain. 2 months before admission he had complained of diarrhoea but a colonoscopy showed no abnormalities. Physical examination revealed a sPAP of 95 mmHg and bilateral pretibial oedema. A CT scan showed pulmonary artery dilatation with no evidence of emboli. A ventilation/perfusion scan ruled out pulmonary embolism. Laboratory data showed anaemia and increased levels of NT-proBNP (5640 pg·mL⁻¹). Tests for antinuclear antibodies and HIV serology were negative. Gastroscopy revealed diffusely erithematous antral mucosa. Duodenal biopsies and PCR for T. whipplei confirmed the diagnosis of Whipple disease. Transthoracic echocardiography showed a dilated right ventricle (53 mm) with an estimated sPAP of 112 mmHg, Magnetic resonance imaging revealed a right ventricle of 87x53 mm with an ejection fraction of 53% and normal left cavities (fig. 1). Right heart catheterisation confirmed PH (table 1), with a positive response to epoprostenol (mPAP decrease of 13 mmHg, cardiac index increase $> 2 \text{ L} \cdot \text{m}^{-1} \cdot \text{m}^{-2}$). Because biopsy results were not known at the time of catheterisation, the patient was initially treated with amlodipine 20 mg·day⁻¹. 7 days later he was admitted to the hospital with dyspnoea at rest, sPAP 85 mmHg



FIGURE 1 Magnetic resonance image from patient 2 showing marked enlargement of right cardiac chambers.

and oxygen saturation 89%. Chest radiography showed bilateral pleural effusion. Owing to the high suspicion of PH-Whipple disease, 2 g of ceftriaxone every 24 h was started. After 10 days of treatment, with confirmed diagnosis, a significant improvement was noted. Oxygen saturation at rest was 96%. Echocardiography demonstrated a reduction in sPAP (estimated 61 mmHg). Trimethoprim/sulfamethox-azole 160/800 μ g was started after 2 weeks of ceftriaxone. Amlodipine was discontinued 3 months later. 6 months after starting antibiotics the patient was in functional class I, with an estimated sPAP of 41 mmHg and NT-proBNP of 244 pg·mL⁻¹.

Discussion

The first description of Whipple disease was reported in 1907 by George Whipple. The causative agent of this disease is T. whipplei, a Gram-positive Actinobacterium. In 1991, a PCR assay was developed providing an excellent tool for the diagnosis of the disease [3]. Infection occurs via the gastrointestinal route with intensive macrophage recruitment and activation. It predominantly occurs in males (8:1 male-to-female ratio). As in other inflammatory diseases, genetic susceptibility probably plays an important role. A defect in cellular immune response may predispose to infection and might explain the rarity of the disorder despite the ubiquitous presence of T. whipplei, but the immunological defect is, in some way, probably specific to this pathogen since other infections do not occur more frequently. Humoral response does not appear to be affected, with normal levels of IgG and IgM. Moreover, the impaired immunity is probably also increased by the presence of T. whipplei. Macrophages from patients with Whipple disease have a lower ability to phagocytosis and expression of CD11b in circulating cells, a receptor that facilitates cell adhesion, is very low [4]. One of the main features is decreased production of interleukin (IL)-12, a typical cytokine of activated macrophages that is key in T-helper 1 differentiation and, therefore, interferon- γ production [5]. There is also reduced secretion of IL-1, IL-6 and IL-10, but the production of transforming growth factor (TGF)- β is increased. The TGF- β pathway has been shown to be a key role in the development of pulmonary arterial hypertension. Apoptosis of macrophages is another critical event in the pathogenesis of Whipple disease, which seems to be induced by intracellular T. whipplei and may explain the dissemination of the pathogen [6]. These inflammatory changes in the pulmonary arteries and venules are perhaps the basis of the increased pulmonary vascular pressure.

Symptoms are nonspecific but the most typical are arthralgia, diarrhoea, abdominal pain and weight loss, but cardiac and central nervous system involvement may occur. Diagnosis is based on duodenal biopsy with the presence of PAS-positive histiocytes and direct testing for bacterial DNA by PCR. Current treatment consists of ceftriaxone for 2–4 weeks followed by trimethoprim/sulfametoxazole for at least 1 year.

Pulmonary involvement by Whipple disease is not well defined but perhaps is not uncommon, while PH-Whipple disease is extremely rare. The two cases that were first reported were secondary to aortic insufficiency, probably related to endocarditis caused by T. whipplei [7, 8]. Another five cases have been reported [9–13], two of them with haemodynamic studies and only one with vasodilator testing. Pulmonary capillary wedge pressure was normal in our patients but nevertheless we cannot exclude capillary venous involvement. The underlying pathogenic mechanism of PH in Whipple disease has not been clearly established but complete resolution with antibiotics, as presented in our cases, is the strongest evidence for a causal relationship. Pleural biopsies from one patient with confirmed PH-Whipple disease demonstrated subpleural pulmonary arteries with partial luminal obliteration by PAS-positive macrophages and fibrinoid debris [11]. This inflammatory nature of PH-Whipple disease may explain the dramatic response of PH to antibiotic therapy. It is noteworthy that a Jarisch-Herxheimer reaction has been described in one patient, probably related to the strong effect of antibiotics [10]. Another important aspect is the positive response to vasodilator testing in our patients and in the other cases reported previously, as well as the poor results with calcium blockers. One of our patients was initially treated with amlodipine according to the results of vasodilator testing but no significant response was achieved. Similar results were seen in the patient reported by NAJM et al. [12] treated with sildenafil and nifedipine, with minimal early improvement but severe worsening a few months later. We did not perform right heart catheterisation during follow-up due to the excellent outcome of our patients, although it would be very interesting to know if they had normalised haemodynamic values. In both cases, the serial echocardiograms showed progressive improvement and were virtually normal after 10 and 6 months of antibiotic treatment, respectively.

In conclusion, we reported two patients with PH-Whipple disease, an extremely rare association, both with positive vasodilator testing and complete resolution of PH shortly after antibiotic treatment. These results suggest an inflammatory nature of PH and add evidence to causal relationships with Whipple disease. Vasodilators seem to have little efficacy.

@ERSpublications



PH associated with Whipple disease, an infrequent but severe association, responds quickly to antibiotic therapy http://ow.ly/AjsAY

Adolfo Baloira¹, Marta Núñez¹, Manuel Tumbeiro², Isaura Parente-Lamelas², María Bastos³ and Mario Gutiérrez⁴ ¹Dept of Pneumology, Hospital Montecelo, Pontevedra, Spain. ²Dept of Pneumology, Complejo Hospitalario de Orense, Orense, Spain. ³Dept of Cardiology, Hospital Montecelo, Pontevedra, Spain. ⁴Dept of Cardiology, Complejo Hospitalario de Orense, Orense, Spain.

Correspondence: Adolfo Baloira Dept of Pneumology, Hospital Montecelo, Pontevedra, 36071, Spain. E-mail: adolfo.baloira.villar@sergas.es

Received: June 09 2014 | Accepted after revision: July 09 2014

Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

Provenance: Submitted article, peer reviewed.

References

- 1 Marth T, Raoult D. Whipple's disease. Lancet 2003; 361: 239–246.
- 2 Arnol CA, Moreira RK, Lam-Himlin D, et al. Whipple disease a century after the initial description. Am J Surg Pathol 2012; 36: 1066–1073.
- 3 Relman DA, Schmidt TM, MacDermott RP, *et al.* Identification of the uncultured bacillus of Whipple's disease. *N Eng J Med* 1992; 327: 293–301.
- 4 Marth T, Roux M, von Herbay A, *et al.* Persistent reduction of complement receptor 3-α-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. *Clin Immunol Immunopathol* 1994; 72: 217.
- 5 Marth T, Neurath M, Cuccherini BA, *et al.* Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. *Gastroenterology* 1997; 113: 442–428.
- Desnues B, Ihrig M, Raoult D, *et al.* Whipple's disease: a macrophage disease. *Clin Vaccine Immunol* 2006; 13: 170–178.
 Bostwick DG, Bensch KG, Burke JS, *et al.* Whipple's disease presenting as aortic insufficiency. *N Engl J Med* 1981; 305: 995–998.
- Morrison DA, Gay RG, Feldshon D, et al. Severe pulmonary hypertension in a patient with Whipple's disease. Am J Med 1985; 79: 263–267.
- 9 Riemer H, Hainz R, Stain C, *et al.* Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease. *Thorax* 1997; 52: 1014–1015.
- 10 Peschard S, Brinkane A, Bergheul S, et al. Maladie de Whipple associée a une hypertension artérielle pulmonaire. Réaction de Jarisch-Herxheimer après antibiothérapie [Whipple disease associated with pulmonary arterial hypertension. Jarisch-Herxheimer reaction after antibiotic therapy]. Presse Med 2001; 30: 1549–1551.
- 11 Lyle PL, Weber RD, Bogarin J, *et al.* Reversible pulmonary hypertension in Whipple disease: a case report with clinicopathological implications, and literature review. *BMJ Case Rep* 2009 [In press DOI: 10.1136/ bcr.06.2008.0095].
- 12 Najm S, Hajjar J, Nelson RP Jr, *et al.* Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements. *Can Respir J* 2011; 18: e70–e72.
- 13 Hoskote SS, Georgescu A, Ganjhu L, et al. Resolution of Whipple disease-induced pulmonary hypertension following antibiotic therapy. Am J Ther 2014; 21: e143–e147.

Eur Respir Rev 2014; 23: 533–536 | DOI: 10.1183/09059180.00005714 | Copyright ©ERS 2014 ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.